Fortis Health.

how big is Fortis Health.?

As of Jun 06, Fortis Healthcare Ltd has a market capitalization of 57,671.25 Cr, with recent net sales of 7,782.75 Cr and net profit of 774.21 Cr over the last four quarters. Shareholder's funds are 7,662.90 Cr, and total assets amount to 12,971.37 Cr as of Mar 2024.

Market Cap: As of Jun 06, Fortis Healthcare Ltd has a market capitalization of 57,671.25 Cr, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, the sum of Net Sales is 7,782.75 Cr, and the sum of Net Profit is 774.21 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is also on a Consolidated basis for the latest annual period ending in Mar 2024. The Shareholder's Funds are reported at 7,662.90 Cr, and the Total Assets amount to 12,971.37 Cr.

When is the next results date for Fortis Health.?

No Upcoming Board Meetings

Has Fortis Health. declared dividend?

Fortis Healthcare Ltd has declared a 10% dividend, amounting to ₹1 per share, with an ex-date of July 24, 2024. The dividend yield is 0.13%, and the company has shown significant price appreciation and total returns across various periods.

Fortis Healthcare Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 24 Jul 24<BR><BR>Dividend Yield: 0.13%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 6.7%, the dividend return was 0%, resulting in a total return of 6.7%.<BR><BR>Over the past year, the price return was 71.16%, the dividend return was 0.21%, leading to a total return of 71.37%.<BR><BR>In the 2-year period, the price return was 170.94%, with a dividend return of 0.65%, culminating in a total return of 171.59%.<BR><BR>For the 3-year period, the price return was 214.91%, the dividend return was 0.87%, resulting in a total return of 215.78%.<BR><BR>In the 4-year period, the price return was 236.71%, with a dividend return of 0.84%, leading to a total return of 237.55%.<BR><BR>Over the last 5 years, the price return was 548.54%, the dividend return was 1.56%, resulting in a total return of 550.1%.<BR><BR>Overall, Fortis Healthcare Ltd has declared a dividend while also demonstrating significant price appreciation over the years, with total returns reflecting strong performance across all periods. The dividend yield remains modest, indicating that the company is focusing on growth alongside returning value to shareholders.

Who are the peers of the Fortis Health.?

Fortis Health's peers include Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Aster DM Health, Krishna Institute, Rainbow Child, Dr. Agarwal's Health, and Jupiter Life Line. Fortis Health has good management risk and growth, with a 1-year return of 60.01%, lower than Krishna Institute's 85.47%.

Peers: The peers of Fortis Health are Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Aster DM Health, Krishna Institu, Rainbow Child, Dr Agarwal's Hea, and Jupiter Life Lin.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Krishna Institu, Rainbow Child, Dr Agarwal's Hea, Jupiter Life Lin, and the rest. Good management risk is found at Fortis Health. Average management risk is present at Aster DM Health. Excellent growth is noted at Max Healthcare and Apollo Hospitals, while good growth is observed at Fortis Health, Narayana Hrudaya, and Dr Agarwal's Hea. Below average growth is seen at Aster DM Health and Krishna Institu, and the rest. Excellent capital structure is noted at Max Healthcare, Global Health, Krishna Institu, and the rest, while good capital structure is found at Fortis Health, Narayana Hrudaya, Rainbow Child, and Dr Agarwal's Hea. Average capital structure is present at Apollo Hospitals and Aster DM Health.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Krishna Institu at 85.47%, while the lowest is Dr Agarwal's Hea with no available data. Fortis Health's 1-year return is 60.01%, which is significantly higher than Dr Agarwal's Hea but lower than Krishna Institu. Additionally, Aster DM Health and Dr Agarwal's Hea have negative six-month returns.

Who are in the management team of Fortis Health.?

As of March 2023, the management team of Fortis Health includes Ashutosh Raghuvanshi (Managing Director & CEO), Ravi Rajagopal (Chairman), and several independent and non-executive directors, totaling 12 members with diverse expertise.

As of March 2023, the management team of Fortis Health includes the following members:<BR><BR>1. Suvalaxmi Chakraborty - Independent Director<BR>2. Ravi Rajagopal - Chairman & Independent Director<BR>3. Indrajit Banerjee - Independent Director<BR>4. Ashutosh Raghuvanshi - Managing Director & CEO<BR>5. Sim Heng Joo Joe - Non Executive Director<BR>6. Shailaja Chandra - Independent Director<BR>7. Dilip Kadambi - Non Executive Director<BR>8. Joerg Ayrla - Non Executive Director<BR>9. Murlee Manohar Jain - Company Secretary & Compliance Officer<BR>10. Tomo Nagahiro - Non Executive Director<BR>11. Mehmet Ali Aydinlar - Non Executive Director<BR>12. Lim Tsin Lin - Non Executive Director<BR><BR>This diverse team brings a range of expertise and leadership to Fortis Health.

What does Fortis Health. do?

Fortis Healthcare Ltd is a leading large-cap healthcare services provider in India, with recent net sales of ₹20,072 Cr and a net profit of ₹1,839 Cr as of March 2025. The company operates hospitals and has a market capitalization of ₹60,744 Cr.

Overview:<BR>Fortis Healthcare Ltd is one of the largest healthcare services providers in India, operating in the hospital industry and classified as a large-cap company.<BR><BR>History:<BR>Fortis Healthcare Ltd was incorporated in an unspecified year and has maintained its status as a leading healthcare provider. The latest quarterly results reported are for March 2025, showing significant sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 20,072 Cr (Quarterly Results - Mar 2025)<BR>Most recent Net Profit: 1,839 Cr (Quarterly Results - Mar 2025)<BR>Market-cap value: INR 60,744 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 72.00<BR>Industry P/E: 59<BR>Dividend Yield: 0.12%<BR>Debt-Equity: 0.22<BR>Return on Equity: 9.41%<BR>Price to Book: 6.78<BR><BR>Contact Details:<BR>Address: Fortis Hospital Sector-62, Phase-VIII Mohali Punjab : 160062<BR>Phone: 91-172-5096001<BR>Email: secretarial@fortishealthcare.com<BR>Website: http://www.fortishealthcare.com

Who are the top shareholders of the Fortis Health.?

The top shareholders of Fortis Health include promoters holding 31.17%, mutual funds with 25.77%, and foreign institutional investors (FIIs) at 27.4%. HDFC Mutual Fund is the largest public shareholder, owning 6%, while individual investors hold 10.22%.

The top shareholders of Fortis Health include a mix of promoters, mutual funds, and foreign institutional investors (FIIs). The majority shareholders are the promoters, with Northern Tk Venture Pte. Ltd. holding the highest stake at 31.17%. Mutual funds collectively hold 25.77% of the shares through 27 schemes, while FIIs own 27.4% of the company through 389 different investors. The highest public shareholder is HDFC Mutual Fund, specifically through the HDFC S&P BSE 500 ETF, which holds 6%. Additionally, individual investors account for 10.22% of the shareholding.

Are Fortis Health. latest results good or bad?

Fortis Healthcare's latest results are positive, with a record Profit After Tax of Rs 250.67 crore and net sales of Rs 2,166.72 crore, indicating strong growth. However, rising interest expenses and an increased debt-equity ratio suggest potential liquidity concerns, leading to a 'Hold' rating from MarketsMOJO.

Fortis Healthcare's latest results for the quarter ending June 2025 are quite positive. The company reported a Profit After Tax (PAT) of Rs 250.67 crore, which is the highest in the last five quarters, indicating strong growth. Net sales also reached a peak of Rs 2,166.72 crore, reflecting a solid upward trend with a quarter-on-quarter growth of 7.95%.<BR><BR>Additionally, the operating profit (PBDIT) was recorded at Rs 490.67 crore, also the highest in five quarters, with an operating profit margin of 22.65%, showcasing improved operational efficiency. The Profit Before Tax (PBT) increased significantly by 25.3% compared to the average of the previous four quarters.<BR><BR>However, there are some challenges to consider. Interest expenses have risen sharply to Rs 137.13 crore, a 68.09% increase, which suggests higher borrowing costs. The debt-equity ratio has also increased to 0.28 times, indicating greater leverage and potential liquidity concerns.<BR><BR>Overall, while the financial performance shows strong growth and efficiency improvements, the rising interest expenses and increased leverage are factors that need to be monitored. The stock is currently rated as a 'Hold' by MarketsMOJO, reflecting a cautious outlook amidst these challenges.

Is Fortis Health. technically bullish or bearish?

As of November 4, 2025, Fortis Health's technical trend is mildly bullish, supported by positive MACD and moving averages, though caution is advised due to mixed signals from the weekly KST and Dow Theory.

As of 4 November 2025, the technical trend for Fortis Health has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish, indicating positive momentum. The daily moving averages are bullish, supporting the mildly bullish stance. However, the weekly KST is mildly bearish, and the Dow Theory shows a mildly bearish signal on the weekly timeframe, suggesting some caution. The Bollinger Bands indicate a mildly bullish outlook on both weekly and monthly timeframes. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some mixed signals from KST and Dow Theory.

How has been the historical performance of Fortis Health.?

Fortis Health has shown consistent growth in net sales and profitability from March 2019 to March 2025, with net sales increasing from 4,469.36 Cr to 7,782.75 Cr and profit after tax rising from a loss of 588.12 Cr to 797.86 Cr. The company has demonstrated a strong recovery, with significant improvements in operating profit and cash flow during this period.

Answer:<BR>The historical performance of Fortis Health shows a consistent growth trajectory in net sales and profitability over the years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Fortis Health's net sales have steadily increased from 4,469.36 Cr in March 2019 to 7,782.75 Cr in March 2025, reflecting a robust growth trend. The total operating income followed a similar pattern, rising from 4,469.36 Cr to 7,782.75 Cr during the same period. The operating profit (PBDIT) also demonstrated significant improvement, increasing from 317.62 Cr in March 2019 to 1,654.88 Cr in March 2025, with an operating profit margin that improved from 5.04% to 20.4%. Profit before tax reached 995.52 Cr in March 2025, up from a loss of 474.51 Cr in March 2019, while profit after tax rose to 797.86 Cr from a loss of 588.12 Cr in March 2019. The consolidated net profit has shown a positive trend, increasing from -298.93 Cr in March 2019 to 774.21 Cr in March 2025. The company's total assets have grown from 10,954.94 Cr in March 2020 to 13,376.98 Cr in March 2025, and total liabilities increased from 10,954.94 Cr to 13,376.98 Cr during the same period. Cash flow from operating activities improved significantly, reaching 1,423.00 Cr in March 2025 compared to 171.00 Cr in March 2020. Overall, Fortis Health has demonstrated a strong recovery and growth in financial performance over the years.

How has been the historical performance of Fortis Health.?

Fortis Health has shown consistent growth in net sales and profitability, with net sales increasing from 4,469.36 Cr in March 2019 to 7,782.75 Cr in March 2025, and profit after tax improving from a loss of 588.12 Cr to a profit of 797.86 Cr during the same period. The company's financial performance reflects a positive growth trajectory with rising revenues and operating profits.

Answer:<BR>The historical performance of Fortis Health shows a consistent growth in net sales and profitability over the years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Fortis Health has demonstrated a steady increase in net sales, rising from 4,469.36 Cr in March 2019 to 7,782.75 Cr in March 2025. The total operating income has followed a similar upward trajectory, reaching 7,782.75 Cr in March 2025, compared to 4,469.36 Cr in March 2019. The company has also improved its operating profit (PBDIT), which increased from 317.62 Cr in March 2019 to 1,654.88 Cr in March 2025, reflecting an operating profit margin of 20.4% in the latest fiscal year. Profit before tax has shown a positive trend, moving from a loss of 474.51 Cr in March 2019 to a profit of 995.52 Cr in March 2025. Consequently, profit after tax has also improved significantly, from a loss of 588.12 Cr in March 2019 to a profit of 797.86 Cr in March 2025. The company's total assets have increased from 10,954.94 Cr in March 2020 to 13,376.98 Cr in March 2025, while total liabilities have also risen, indicating a growing business scale. Cash flow from operating activities has improved, reaching 1,423.00 Cr in March 2025, although the company experienced a net cash outflow of 69.00 Cr in the same period. Overall, Fortis Health's financial performance reflects a positive growth trajectory with increasing revenues and profitability over the years.

Is Fortis Health. overvalued or undervalued?

As of December 4, 2025, Fortis Health is considered expensive and overvalued with a PE ratio of 66.42, higher than its peers, despite a strong YTD return of 23.12% compared to the Sensex's 9.12%.

As of 4 December 2025, the valuation grade for Fortis Health has moved from very expensive to expensive. The company is currently considered overvalued based on its high valuation ratios, including a PE ratio of 66.42, an EV to EBITDA ratio of 37.50, and a Price to Book Value of 7.09. <BR><BR>In comparison to its peers, Fortis Health's PE ratio is higher than Apollo Hospitals at 61.81 and Narayana Hrudaya at 46.47, both of which are also categorized as expensive. The company's recent stock performance shows a YTD return of 23.12%, significantly outperforming the Sensex's return of 9.12% during the same period, which may indicate strong market interest despite its overvaluation.

Should I buy, sell or hold Fortis Healthcare Ltd?

Why is Fortis Healthcare Ltd falling/rising?

As of 13-Mar, Fortis Healthcare Ltd's stock price is declining at 839.65, down 2.39%. Despite strong long-term growth, recent performance issues and financial metrics indicate potential strain, contributing to its underperformance.

As of 13-Mar, Fortis Healthcare Ltd's stock price is falling, currently at 839.65, which reflects a change of -20.6 (-2.39%). The stock has been underperforming, having lost -4.71% over the last three days and is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, the stock's performance today has underperformed its sector by -0.93%. <BR><BR>In terms of broader performance metrics, the stock has seen a decline of -5.92% over the past week and -8.43% over the past month, although it has shown strong returns over the longer term, with a +39.01% increase over the past year and +213.24% over the past three years. However, the recent declines may be attributed to several negative factors, including a low Operating Profit to Interest ratio of 5.90 times and a high Debt to Equity ratio of 0.34 times, which indicate potential financial strain. <BR><BR>Despite the strong long-term growth in operating profit and high institutional holdings, the current market sentiment appears to be influenced by the stock's recent performance and valuation concerns, leading to its decline.

Why is Fortis Healthcare Ltd falling/rising?

As of 14-Mar, Fortis Healthcare Ltd's stock price is Rs 839.65, down 2.39%, reflecting a consistent downward trend with losses over the past week and month. Despite increased investor participation, negative sentiment persists due to underperformance against sector benchmarks and concerning financial ratios.

As of 14-Mar, Fortis Healthcare Ltd's stock price is falling, currently at Rs 839.65, which reflects a decrease of Rs 20.6 or 2.39%. The stock has been underperforming, having lost 4.71% over the last three days, and it is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, the stock has experienced a decline of 5.92% over the past week and 8.43% over the past month, indicating a consistent downward trend.<BR><BR>The stock's performance today has also underperformed its sector by 0.93%. It reached an intraday low of Rs 837.5, marking a decrease of 2.64%. Despite a rise in investor participation, with delivery volume increasing by 127.47% against the 5-day average, the overall sentiment appears negative due to the stock's consecutive falls and its current valuation metrics. <BR><BR>Moreover, while the company has a strong ability to service debt and has shown healthy long-term growth, certain financial ratios, such as the lowest Operating Profit to Interest ratio and the highest Debt-Equity ratio, suggest potential concerns regarding its financial health. The stock is also considered expensive relative to its returns, with a PEG ratio of 2.3, which may deter investors. Overall, these factors contribute to the stock's current decline.

Why is Fortis Healthcare Ltd falling/rising?

As of 15-Mar, Fortis Healthcare Ltd's stock price is at 839.65, down 2.39%, and has underperformed significantly over the past week and month. Despite a strong annual return of 39.01%, concerns over financial metrics and recent declines indicate a downward trend in the stock's performance.

As of 15-Mar, Fortis Healthcare Ltd's stock price is falling, currently at 839.65, which reflects a decrease of 20.6 points or 2.39%. The stock has been underperforming, having lost 4.71% over the last three days and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, the stock has experienced a decline of 5.92% over the past week and 8.43% over the past month, although it has shown a strong performance over the past year with a return of 39.01%.<BR><BR>Today's performance indicates that the stock has underperformed its sector by 0.93%. The intraday low reached was Rs 837.5, marking a 2.64% drop. Despite these negative movements, there has been a notable increase in investor participation, with delivery volume rising by 127.47% against the 5-day average, suggesting some level of interest from investors.<BR><BR>Several financial metrics indicate potential concerns. The company's operating profit to interest ratio is at its lowest, and the debt-equity ratio is at its highest, which may contribute to investor apprehension. Furthermore, while the stock has generated a significant return over the past year, the profits have only increased by 27.8%, leading to a PEG ratio of 2.3, which suggests that the stock may be overvalued relative to its growth.<BR><BR>Overall, the combination of recent price declines, underperformance against benchmarks, and concerning financial ratios contributes to the current downward trend in Fortis Healthcare Ltd's stock price.

Which are the latest news on Fortis Health.?